Non-small cell lung cancer
EGFR, ALK, KRAS G12C and the ADC wave in first and later lines.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 14 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for non-small cell lung carcinoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 16 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | genetic literature | Clinical | Pathways | Literature | Animal models | RNA expr. |
|---|---|---|---|---|---|---|---|---|---|
| EGFRPeds RMTL epidermal growth factor receptor | 0.89 | 0.93 | 0.93 | ||||||
| KRAS KRas proto-oncogene, GTPase | 0.83 | – | 0.92 | ||||||
| ALKPeds RMTL ALK receptor tyrosine kinase | 0.81 | – | 0.82 | ||||||
| ERBB2Peds RMTL erb-b2 receptor tyrosine kinase 2 | 0.81 | – | 0.81 | ||||||
| ROS1Peds RMTL ROS proto-oncogene 1, receptor tyrosine kinase | 0.81 | 0.31 | 0.86 | ||||||
| METPeds RMTL MET proto-oncogene, receptor tyrosine kinase | 0.81 | – | 0.84 | ||||||
| DICER1 dicer 1, ribonuclease III | 0.79 | 0.86 | 0.84 | ||||||
| RETPeds RMTL ret proto-oncogene | 0.78 | – | 0.76 | ||||||
| TP53Peds RMTL tumor protein p53 | 0.77 | – | 0.92 | ||||||
| BRAFPeds RMTL B-Raf proto-oncogene, serine/threonine kinase | 0.76 | – | 0.87 | ||||||
| ERBB4 erb-b2 receptor tyrosine kinase 4 | 0.76 | – | 0.84 | ||||||
| EML4 EMAP like 4 | 0.75 | – | 0.94 | ||||||
| STK11 serine/threonine kinase 11 | 0.74 | – | 0.86 | ||||||
| KIF5B kinesin family member 5B | 0.72 | – | 0.93 | ||||||
| CCDC6 coiled-coil domain containing 6 | 0.72 | – | 0.88 | ||||||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.71 | – | 0.83 | ||||||
| POLD1 DNA polymerase delta 1, catalytic subunit | 0.71 | – | 0.76 | ||||||
| NTRK1 neurotrophic receptor tyrosine kinase 1 | 0.71 | – | 0.68 | ||||||
| KDR kinase insert domain receptor | 0.71 | – | 0.64 | ||||||
| NRG1 neuregulin 1 | 0.70 | 0.90 | 0.84 | ||||||
| CD274Peds RMTL CD274 molecule | 0.70 | – | 0.60 | ||||||
| POLE DNA polymerase epsilon, catalytic subunit | 0.70 | – | 0.67 | ||||||
| RB1 RB transcriptional corepressor 1 | 0.70 | – | 0.84 | ||||||
| NPM1 nucleophosmin 1 | 0.70 | – | 0.65 | ||||||
| KEAP1 kelch like ECH associated protein 1 | 0.69 | – | 0.90 | ||||||
| NTRK2 neurotrophic receptor tyrosine kinase 2 | 0.69 | – | 0.69 | ||||||
| SMARCA4 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4 | 0.69 | – | 0.89 | ||||||
| NTRK3 neurotrophic receptor tyrosine kinase 3 | 0.69 | – | 0.69 | ||||||
| RBM10 RNA binding motif protein 10 | 0.69 | – | 0.89 | ||||||
| CD74 CD74 molecule | 0.68 | – | 0.89 | ||||||
| FLT4 fms related receptor tyrosine kinase 4 | 0.68 | – | 0.69 | ||||||
| CTNNB1Peds RMTL catenin beta 1 | 0.68 | – | 0.86 | ||||||
| TERTPeds RMTL telomerase reverse transcriptase | 0.67 | 0.86 | 0.62 | ||||||
| CDKN2A cyclin dependent kinase inhibitor 2A | 0.66 | 0.19 | 0.84 | ||||||
| SDC4 syndecan 4 | 0.66 | – | 0.85 | ||||||
| FGFR2 fibroblast growth factor receptor 2 | 0.65 | 0.56 | 0.68 | ||||||
| ARID1A AT-rich interaction domain 1A | 0.65 | – | 0.84 | ||||||
| TP63 tumor protein p63 | 0.65 | 0.88 | 0.64 | ||||||
| PDGFRAPeds RMTL platelet derived growth factor receptor alpha | 0.64 | – | 0.57 | ||||||
| PDGFRBPeds RMTL platelet derived growth factor receptor beta | 0.64 | – | 0.66 | ||||||
| TYMSPeds RMTL thymidylate synthetase | 0.63 | – | – | ||||||
| FGFR3 fibroblast growth factor receptor 3 | 0.63 | – | 0.66 | ||||||
| PDCD1Peds RMTL programmed cell death 1 | 0.63 | – | – | ||||||
| VEGFA vascular endothelial growth factor A | 0.63 | – | – | ||||||
| TUBB tubulin beta class I | 0.63 | – | – | ||||||
| ERBB3 erb-b2 receptor tyrosine kinase 3 | 0.63 | – | 0.67 | ||||||
| TUBA1B tubulin alpha 1b | 0.63 | – | – | ||||||
| TUBA1C tubulin alpha 1c | 0.63 | – | – | ||||||
| RRM2 ribonucleotide reductase regulatory subunit M2 | 0.62 | – | – | ||||||
| FGFR1 fibroblast growth factor receptor 1 | 0.62 | – | 0.69 |
57 biomarkers in Non-small cell lung cancer have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Lung Non-small Cell Carcinoma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 452 accepted items exist; the first 100 were read. This is the published evidence, not treatment advice.
- v::ALK Fusion level A
- EGFR T790M level A
- EGFR L858R OR EGFR Exon 19 Deletion level A
- v::ROS1 Fusion level A
- EGFR Exon 20 Insertion level A
- EGFR L858R level A
- EGFR Mutation level A
- EGFR Exon 19 Deletion level A
- ERBB2 Exon 20 Insertion level A
- ERBB2 Mutation level A
- KRAS Mutation level A
- v::RET Fusion level A